International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8076521
Original Article
Hyponatremia as A Prognostic Indicator in Acute Coronary Syndrome
 ,
Published
June 24, 2023
Abstract
Background: Hyponatremia, characterized by low serum sodium levels, has been identified as a potential prognostic marker in acute coronary syndrome (ACS). However, its precise relationship with ACS prognosis remains unclear, necessitating further investigation. Aim: This study aims to determine the incidence of hyponatremia in ACS patients and assess its role as a prognostic indicator. Additionally, the correlation between hyponatremia levels and left ventricular dysfunction (LVD) on 2D echocardiography will be evaluated. Results: The study included 40 ACS patients, predominantly middle-aged males with evidence of cardiac muscle damage and moderate LVD. The prevalence of hyponatremia varied among different ACS types, with higher rates observed in ST-elevation myocardial infarction (STEMI) subtypes. Significant associations were found between LVD and the presence of hyponatremia, as well as between hyponatremia and mortality in ACS patients. Conclusion: Hyponatremia appears to be prevalent in ACS patients and may serve as a poor prognostic indicator. Its association with LVD and increased mortality highlights the importance of monitoring and managing sodium levels in ACS patients. Further research is needed to explore potential interventions and strategies for improving outcomes in ACS patients with hyponatremia.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
1609 Views
454 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved